Featuring A. Trevor Thrall, Associate Professor, School of Policy, Government, and International Affairs, George Mason University; and Erik Goepner, Doctoral student in public policy, George Mason University; with comments by Betsy Woodruff, Politics Reporter, The Daily Beast; Emily Ekins, Research Fellow, Cato Institute; and Aaron Schumacher, Director, International, Foreign Policy Group, and Senior Vice President, Young Professionals in Foreign Policy; moderated by Christopher Preble, Vice President for Defense and Foreign Policy Studies, Cato Institute.
A limited constitutional government calls for a rules-based, freemarket monetary system, not the topsy-turvy fiat dollar that now exists under central banking. This issue of the Cato Journal examines the case for alternatives to central banking and the reforms needed to move toward free-market money.
Americans are finally enjoying an improving economy after years of recession and slow growth. The unemployment rate is dropping, the economy is expanding, and public confidence is rising. Surely our economic crisis is behind us. Or is it? In Going for Broke: Deficits, Debt, and the Entitlement Crisis, Cato scholar Michael D. Tanner examines the growing national debt and its dire implications for our future and explains why a looming financial meltdown may be far worse than anyone expects.
The Cato Institute has released its 2014 Annual Report, which documents a dynamic year of growth and productivity. “Libertarianism is not just a framework for utopia,” Cato’s David Boaz writes in his book, The Libertarian Mind. “It is the indispensable framework for the future.” And as the new report demonstrates, the Cato Institute, thanks largely to the generosity of our Sponsors, is leading the charge to apply this framework across the policy spectrum.
Featuring Sen. Byron L. Dorgan (D-ND); and Roger Pilon, Vice President for Legal Affairs, Cato Institute.
Americans look abroad and see prescription drugs, made in the United States, sold at a small fraction of the price they’re paying here for the same drugs. Yet they can’t order such drugs legally because American law forbids the “reimportation” of drugs. That ban enables American drug manufacturers to recover their full costs, including high research and development costs, in the domestic market, then sell abroad to socialized medical systems at far below true cost. In effect, as with defense, the rest of the world is riding free while Americans pick up the full costs of drug R&D. Is it time for a free market in prescription drugs? And will opening the market to allow reimportation from Canada only, a compromise some people are proposing, lower prices for Americans, or simply raise them for Canadians?